RARA CRAFT DATABASE for FDA Medical Devices

FDA Guidance and Notices, March 2025: Sex-Specific Data in Device Clinical Studies and a Recognized Standards Update

日本語版

Two things happened on March 31, 2025. FDA issued final guidance on evaluating sex-specific data in medical device clinical studies, and a federal district court vacated FDA's 2024 final rule on laboratory developed tests (LDTs). FDA later issued a final rule on September 19, 2025, returning to the earlier provisions.

If you rely on declarations of conformity, look at the March 20 Federal Register notice updating the list of recognized consensus standards (Recognition List 063). On March 14, FDA wrote to health care providers about a shortage of hemodialysis bloodlines.

Final guidance

In the Federal Register

Safety communications and other updates

Also this month

  • March 31: A federal district court vacated FDA's 2024 final rule on LDTs.

Note: dates are FDA issue dates or Federal Register publication dates. Linked pages may now show a later version.

RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.

← All articles